Literature DB >> 28362954

Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France.

Bertrand Dunogué1,2, Benoit Pilmis1,2, Nizar Mahlaoui2,3,4,5, Caroline Elie6, Hélène Coignard-Biehler1,2, Karima Amazzough1,2, Nicolas Noël7, Hélène Salvator8, Emilie Catherinot8, Louis-Jean Couderc8, Harry Sokol9, Fanny Lanternier1,2,4, Fanny Fouyssac10, Julie Bardet11, Jacinta Bustamante4,12,13,14, Marie-Anne Gougerot-Pocidalo15, Vincent Barlogis16, Agathe Masseau17, Isabelle Durieu18, Marc Lecuit1,2,4,19, Felipe Suarez20,21, Alain Fischer2,3,4,22,23, Stéphane Blanche2,3, Olivier Hermine20,21, Olivier Lortholary1,2,4.   

Abstract

Background: Although prognosis of Chronic Granulomatous Disease (CGD) has greatly improved, few studies have focused on its long-term outcome. We studied the clinical course and sequelae of CGD patients diagnosed before age 16, at various adult time points. Method: Cross-sectional French nationwide retrospective study of patients screened through the National Reference Center for Primary Immunodeficiencies (CEREDIH) registry.
Results: Eighty CGD patients (71 males [88.7%], 59 X-linked [73.7%], median age 23.9 years [minimum, 16.6; maximum, 59.9]) were included, Median ages at diagnosis and last follow-up were 2.52 and 23.9 years, respectively. Seven patients underwent hematopoietic stem cell transplantation. A total of 553 infections requiring hospitalization occurred in 2017 patient-years. The most common site of infection was pulmonary (31%). Aspergillus spp. (17%) and Staphylococcus aureus (10.7%) were the commonest pathogens. A total of 224 inflammatory episodes occurred in 71 patients, mainly digestive (50%). Their characteristics as well as their annual frequency did not vary before and after age 16. Main sequelae were a small adult height and weight and mild chronic restrictive respiratory failure. At age 16, only 53% of patients were in high school. After age 30 years, 9/13 patients were working. Ten patients died during adulthood. Conclusions: Adult CGD patients displayed similar characteristics and rates of severe infections and inflammatory episodes that those of childhood. The high rate of handicap has become a matter of medical and social consideration. Careful follow-up in centers of expertise is strongly recommended and an extended indication of curative treatment by HSCT should be considered.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adulthood; chronic granulomatous disease; primary immunodeficiency; sequelae; transition

Mesh:

Year:  2017        PMID: 28362954     DOI: 10.1093/cid/ciw837

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

Review 1.  Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

Authors:  Emma C Morris
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network.

Authors:  Jennifer R Yonkof; Ashish Gupta; Pingfu Fu; Elizabeth Garabedian; Jignesh Dalal
Journal:  J Clin Immunol       Date:  2019-05-20       Impact factor: 8.317

3.  Late diagnosis of chronic granulomatous disease.

Authors:  T Barkai; R Somech; A Broides; R Gavrieli; B Wolach; N Marcus; D Hagin; T Stauber
Journal:  Clin Exp Immunol       Date:  2020-07-13       Impact factor: 4.330

Review 4.  Advances and highlights in primary immunodeficiencies in 2017.

Authors:  Javier Chinen; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2018-08-29       Impact factor: 10.793

5.  Macrophage NOX2 NADPH oxidase maintains alveolar homeostasis in mice.

Authors:  Sourav Bhattacharya; Rachel A Idol; Wei Yang; Jorge David Rojas Márquez; Yanan Li; Guangming Huang; Wandy L Beatty; Jeffrey J Atkinson; John H Brumell; Juhi Bagaitkar; Jeffrey A Magee; Mary C Dinauer
Journal:  Blood       Date:  2022-05-12       Impact factor: 25.476

6.  Neutrophil-Derived Tumor Necrosis Factor Drives Fungal Acute Lung Injury in Chronic Granulomatous Disease.

Authors:  R Elaine Cagnina; Kathryn R Michels; Alexandra M Bettina; Marie D Burdick; Yogesh Scindia; Zhimin Zhang; Thomas J Braciale; Borna Mehrad
Journal:  J Infect Dis       Date:  2021-10-13       Impact factor: 5.226

7.  Clinical and Immunological Characteristics of 63 Patients with Chronic Granulomatous Disease: Hacettepe Experience.

Authors:  Halil Tuna Akar; Saliha Esenboga; Deniz Cagdas; Sevil Oskay Halacli; Begum Ozbek; Karin van Leeuwen; Martin de Boer; Cagman Sun Tan; Yavuz Köker; Dirk Roos; Ilhan Tezcan
Journal:  J Clin Immunol       Date:  2021-02-24       Impact factor: 8.317

8.  Late diagnosis and advances in genetics of chronic granulomatous disease.

Authors:  G Di Matteo; A Finocchi
Journal:  Clin Exp Immunol       Date:  2020-12-13       Impact factor: 4.330

Review 9.  Chronic Granulomatous Disease: a Comprehensive Review.

Authors:  Hsin-Hui Yu; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

10.  Genetic, Immunological, and Clinical Features of the First Mexican Cohort of Patients with Chronic Granulomatous Disease.

Authors:  Lizbeth Blancas-Galicia; Eros Santos-Chávez; Caroline Deswarte; Quentin Mignac; Isabel Medina-Vera; Ximena León-Lara; Manon Roynard; Selma C Scheffler-Mendoza; Ricardo Rioja-Valencia; Alexandra Alvirde-Ayala; Saul O Lugo Reyes; Tamara Staines-Boone; Jorge García-Campos; Omar J Saucedo-Ramírez; Blanca E Del-Río Navarro; Antonio Zamora-Chávez; Arturo López-Larios; Susana García-Pavón-Osorio; Eugenia Melgoza-Arcos; María R Canseco-Raymundo; Dolores Mogica-Martínez; Marco Venancio-Hernández; Daniel Pacheco-Rosas; Sigifredo Pedraza-Sánchez; Martha Guevara-Cruz; Federico Saracho-Weber; Berenise Gámez-González; Guillermo Wakida-Kuzunoki; Ana R Morán-Mendoza; Ana P Macías-Robles; Roselia Ramírez-Rivera; Eugenia Vargas-Camaño; Carmen Zarate-Hernández; Héctor Gómez-Tello; Emmanuel Ramírez-Sánchez; Fredy Ruíz-Hernández; Domingo Ramos-López; Héctor Acuña-Martínez; María L García-Cruz; María G Román-Jiménez; Marina G González-Villarreal; Aristóteles Álvarez-Cardona; Beatriz A Llamas-Guillén; Jennifer Cuellar-Rodríguez; Alberto Olaya-Vargas; Nideshda Ramírez-Uribe; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Francisco J Espinosa-Rosales; Jeanet Serafín-López; Marco Yamazaki-Nakashimada; Sara Espinosa-Padilla; Jacinta Bustamante
Journal:  J Clin Immunol       Date:  2020-02-10       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.